Evidence map›Paper›PMID 30525111›Full record

ArticleExpert review of precision medicine and drug development2018

Epigenetic inhibitors for the precision treatment of

Takeshi Fukumoto, Rugang Zhang, Benjamin G Bitler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert review of precision medicine and drug development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Takeshi FukumotoGene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104.
Rugang ZhangGene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104.
Benjamin G BitlerDepartment of Obstetrics & Gynecology, University of Colorado Anschutz Medical Campus, Research Complex-2; MS8613, 12700 East 19th Avenue, Aurora, Colorado 80045.

Funding

Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerR01CA202919 · NCI · WISTAR INSTITUTE · PI Xi Chen, Rugang Zhang · 2016 to 2026
$4.1M
Targeting EZH2 in CARM1-expressing epithelial ovarian cancerR01CA163377 · NCI · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2012 to 2021
$3.7M
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancerR00CA194318 · NCI · UNIVERSITY OF COLORADO DENVER · PI BITLER, BENJAMIN G · 2017 to 2019
$745k
NCI NIH HHS R00 CA194318NCI NIH HHS R01 CA163377NCI NIH HHS R01 CA202919
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ARID1AEpigeneticsEZH2HDACovarian cancerSWI/SNF

Identifiers

PMID30525111
PMCPMC6277026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.